The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...

LONDON (Reuters) -Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the ...

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports ...

Metsera stock bidding war intensifies as Novo and Pfizer race to secure next-gen obesity drug assets amid surging market ...

Live Updates Live Coverage Has Ended Get The Best Vanguard S&P 500 ETF Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on Vanguard S&P 500 ETF, market updates, ...

Here’s a summary of the most significant insider buying and selling activities disclosed on Monday, November 3, 2025.

Weight loss drugs are set to become a disproportionate share of Lilly's business.

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Novo Nordisk's new CEO, Mike Doustdar, is under significant pressure as the company contends with declining stock prices, ...

Animal health company Zoetis (NYSE:ZTS) will be reporting results this Tuesday morning. Here’s what to look for.